The success of CHADN and other metabolic surgeries in improving glucose intolerance, however, raises the question of whether eliminating sympathetic nervous input to the liver alters hepatic responsiveness to insulin or predisposes to low blood sugar leading to a greater risk of iatrogenic hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.